Skip to main content
Qurient Co., Ltd. logo

Qurient Co., Ltd. — Investor Relations & Filings

Ticker · 115180 ISIN · KR7115180002 KO Professional, scientific and technical activities
Filings indexed 436 across all filing types
Latest filing 2026-05-15 Interim / Quarterly Rep…
Country KR South Korea
Listing KO 115180

About Qurient Co., Ltd.

http://www.qurient.com/

Qurient Co., Ltd. is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics for unmet medical needs. The company operates on a proprietary 'Network R&D' model, a virtual approach that manages drug development programs from early discovery through clinical phases. Its pipeline includes Adrixetinib for chronic graft-versus-host disease (cGvHD), Telacebec for the treatment of tuberculosis, and a next-generation dual-payload Antibody-Drug Conjugate (ADC) platform for oncology. Qurient advances its portfolio through global clinical trials and strategic collaborations to address critical diseases.

Recent filings

Filing Released Lang Actions
분기보고서 (2026.03)
Interim / Quarterly Report Classification · 95% confidence The document is labeled “분기보고서” covering the period 2026.01.01–2026.03.31 (the first quarter), contains detailed company overview, changes in subsidiaries, share capital tables, financial statement schedules, and appears to be the full quarterly regulatory filing rather than a mere announcement. This corresponds to an Interim/Quarterly Report. Q1 2026
2026-05-15 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Regulatory Filings
2026-04-30 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Regulatory Filings
2026-04-30 Korean
주식매수선택권행사
Regulatory Filings
2026-04-30 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Regulatory Filings
2026-04-30 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Regulatory Filings
2026-04-30 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.